Perimeter Medical Imaging AI Announces Symposium and Its Participation at ASBrS 2023

Demos of Perimeter S-Series OCT at Perimeter's Booth at the 24^th Annual Meeting of the American Society of Breast Surgeons

TORONTO and DALLAS, April 27, 2023 /CNW/ - (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) – Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced that it will host an educational symposium featuring the Perimeter S-Series OCT technology at the upcoming annual meeting of the American Society of Breast Surgeons (ASBrS) taking place April 26-30, 2023 at the John B. Hynes Veterans Memorial Convention Center in Boston, MA.

#ASBRS23 - 24^th Annual Meeting of the American Society of Breast Surgeons 

Educational Symposium

Steve Sapot, Perimeter's Chief Commercial Officer, stated, "ASBrS is a key conference where breast surgeons meet to share the latest research and education to advance the practice of breast surgery. We are excited to be joined for the symposium by leading breast surgeons, Drs. Beth Anglin, Michele Carpenter, and Beth Dupree, who will share their experiences using S-Series OCT in their ORs to help personalize clinical decisions for each patient at the point of care. In addition, we look forward to connecting ASBrS attendees at Booth #923 in the exhibit hall, where we will be featuring live demos on the S-Series OCT device showing its ability to visualize microscopic features at a 2mm depth – ideal to aid surgeons with real-time clarity on margin status."

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; Perimeter's intention to participate in the American Society of Breast Surgeons (ASBrS) conference; Perimeter's expected marketing and sales activities; and the expected details regarding Perimeter's ongoing clinical trials, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2022, which is available on Perimeter's SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-announces-symposium-and-its-participation-at-asbrs-2023-301809609.html

SOURCE Perimeter Medical Imaging AI, Inc.

Released April 27, 2023